Immunotherapy increase the level of treatment for cervical cancer.

A slow growing cancercan be asymptomatic in early stages. Cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. Preceded by dysplasia, it changes precancerous on the cervix, towards invasive carcinoma.In United States, accounts for 86% of all cancers in women and the peak incidence between the age range of 50 to 55 years. The second most common cancer in the United States with more than 400,000 new cases diagnosed each year. It is observed that the incidence is very high in developing countries.Now, immunotherapy drug uses to saves more lives of cervical cancer patients.

 

www.gapsos.com

Human Papilloma Virus (HPV) spreads through sexual intercourse; it is high risk strains 16 and 18, which cause 70% of all cervical cancer. Other risk factors include having sex an early age, multiple sexual partners, use of diethylstilbestrol drug during pregnancy, long term use of birth control pills, compromised immune system, infections with genital herpes or chronic chlamydial, poor living standards, smoking, and multiple pregnancies.

Early cervical cancer may be asymptomatic, but symptoms include continuous discharge from vagina, abnormal bleeding through vagina during periods, after intercourse, bleeding after menopause, longer and heavier periods than usual.Symptoms of advanced cervical cancer include pelvic pain, fatigue, back pain, single swollen leg, leg pain, heavy bleeding from the vagina, leakage of urine or feces from the vagina, bone fracture, and loss of appetite and weight loss.

This cancer isclassified into six histological types that involve Squamous cell carcinoma (85-90%, rise from ectocervix), Adenocarcima (10-15%, rise from endocervix, common in young groups), Adenosquamous (mix of endometriod and clear cell), Adenomamalignum (extremely well differentiated adenocarcinoma), Small cell carcinoma, and neuroendocrine carcinoma.

The Food and Drug Administration (FDA) approved many immunotherapeutic cancer agents for the treatment of cervical cancer after evaluation under clinical trials. Bevacizumab has received FDA approval for the treatment of metastatic condition of this cancer, in combination with Topotecan and Paclitaxel. Many immunotherapeutic cancer agents are still under evaluation of clinical trials for FDA approval such as ADXS11-001 (Lm-LLO-E7), E6 TCR, and HPV16 E7 peptide-pulsed autologous DCs.

Global Allied Pharmaceuticals (GAP) has new technology to developed advanced treatment based on immunotherapy and antibody drug conjugate. GAP has experts for conducting experiments and clinical trials of newly developed immunotherapeutic cancer agents that involves monoclonal antibodies, therapeutic vaccines, adoptive T cell therapy and many more.